Lay Description

PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.


  • Heart, Vascular and Blood
  • Aging and Geriatric
  • Dementia / Alzheimers
IRB Number
NCT Number
Open to Enrollment
Not set


Eligible Ages
Over 75 Years
Eligible Genders
Accepts Healthy Volunteers

Inclusion Criteria

  • Community-dwelling adults
  • Age 75 years or older

Exclusion Criteria

  • Clinically evident CVD, defined as prior MI, prior stroke, prior revascularization procedure, or a secondary prevention indication for a statin as determined by their clinician.
  • Hospitalization for a primary diagnosis of heart failure in the prior 12 months (Note: History of heart failure without clinically evident cardiovascular disease is not an exclusion)
  • Dementia (clinically evident and/or previously diagnosed)
  • Dependence in any Katz Basic Activities of Daily Living [ADL] (with the exception of urinary or bowel continence)
  • Severe hearing impairment (preventing phone follow up)
  • Severe visual impairment (preventing cognitive testing)
  • Statin use in the past year or for longer than 5 years previously (participant reported)
  • Ineligible to take atorvastatin 40 mg (clinician determined)
  • Documented intolerance to statins
  • Active liver disease

Study Design

Arm Groups

Study Contact

Alice Conde
(210) 617-5190

Tiffany Cortes
(210) 450-8998

Sara Espinoza
(210) 617-5197

Sandra Idar
(210) 450-0568

Nicolas Musi
(210) 562-6140

Alice Conde
(210) 617-5190

Sara Espinoza
(210) 617-5197

Sandra Idar
(210) 450-0568

Principal Investigator
Nicolas Musi